3 FORBES ROAD, LEXINGTON, MA
Principal Accounting Officer Austin Charette Resigns Effective May 29, 2026
Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
Annual Report to Security Holders
Other Events
Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
Closes Transaction with Zydus Pharmaceuticals
Dr. Garo Armen Appointed Interim CFO of Agenus Inc.
Material disclosure
Q1
FY 2025
Q3
Q2
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Correspondence
Submission Upload
Automatic Shelf Registration Statement